• News
    • Opinion Editorial
    • Videos
    • Podcasts
  • Community
    • Members
  • Discussion
  • Groups
    • View All
    • Why Join?
  • Write for us
    Sign in Sign up


    • News
      • Opinion Editorial
      • Videos
      • Podcasts
    • Community
      • Members
    • Discussion
    • Groups
      • View All
      • Why Join?
    • Write for us
    Sign in Sign up

    Tag: Investor Watch

    Cerner's Recent Acquisition Evidences Growing Trend of Combining Healthcare & Research Data to Accelerate Clinical Trials

    Cerner’s Recent Acquisition Evidences Growing Trend of Combining Healthcare & Research Data to Accelerate Clinical Trials

    One of the leading electronic health record (EHR) software vendors in North America positions new offerings to accelerate clinical trials’ transformational activity with real world…

    TrialSite Staff
    TrialSite Staff April 10, 2021
    0 Comments
    University of Edinburgh Spin-out Detects Cancer Earlier Secures £1 to Commercialize cfDNA Breakthrough

    University of Edinburgh Spin-out Detects Cancer Earlier Secures £1m to Commercialize cfDNA Breakthrough

    Scotland is known as a resourceful place and if one cares to understand a bit of economic history, there’s a decent case to be made…

    TrialSite Staff
    TrialSite Staff April 7, 2021
    0 Comments
    Abu Dhabi Wealth Fund Injects £1b into UK Life Sciences Sector

    Abu Dhabi Wealth Fund Injects £1b into UK Life Sciences Sector

    The government of the UK inked a £1 billion deal with Abu Dhabi’s sovereign wealth fund called Mubadala for injection of Middle Eastern capital into the…

    TrialSite Staff
    TrialSite Staff April 3, 2021
    0 Comments
    Julius-Maximilians-University Wuerzburg Licenses Vaccine to Canadian-based Biotech

    Julius-Maximilians-University Wuerzburg Licenses Vaccine to Canadian-based Biotech

    One of Germany’s leading research and teaching universities, Julius-Maximilians-University Wuerzburg (the University) recently announced that a potential COVID-19 vaccine developed there was optioned by a…

    TrialSite Staff
    TrialSite Staff March 17, 2021
    0 Comments
    FDA Greenlights IND for Chinese Biotech Targeting Thymic Carcinoma

    FDA Greenlights IND for Chinese Biotech Targeting Thymic Carcinoma

    A Chinese-based biotech company’s investigational new drug application (IND) was given the nod by the U.S. Food and Drug Administration (FDA), meaning that Alphamab Oncology…

    TrialSite Staff
    TrialSite Staff March 10, 2021
    0 Comments
    New Public Benefit Corp ‘Dr. B’ Matches Vaccine Candidates with Doses Headed for Waste

    New Public Benefit Corp ‘Dr. B’ Matches Vaccine Candidates with Doses Headed for Waste

    Dr. B is a new text service that connects those individuals who would like to be vaccinated with doses of COVID-19 vaccines that would otherwise…

    TrialSite Staff
    TrialSite Staff March 10, 2021
    0 Comments
    Alzheimer’s Drug Discovery Foundation Awards $2m for Promising Swiss Merck Serono Spin-off

    Alzheimer’s Drug Discovery Foundation Awards $2m for Promising Swiss Merck Serono Spin-off

    The Alzheimer’s Drug Discovery Foundation (ADDF) awarded $2.2 million to a biotech venture called Asceneuron SA, an emerging leader in the development of treatments for neurodegenerative diseases…

    TrialSite Staff
    TrialSite Staff March 9, 2021
    0 Comments
    DTx Pharma Completes $100M Series B Financing to Advance its FALCON Platform and Pipeline of RNA Therapeutics

    DTx Pharma Completes $100M Series B Financing to Advance its FALCON Platform and Pipeline of RNA Therapeutics

    DTx Pharma announced today the completion of a $100 million Series B financing. The financing was led by RA Capital Management with participation from new…

    TrialSite Staff
    TrialSite Staff March 5, 2021
    0 Comments
    BlossomHill Therapeutics Completes $71M Series A Round to Progress Pipeline of Small Molecule Drugs for Oncology, Autoimmune Disorders

    BlossomHill Therapeutics Completes $71M Series A Round to Progress Pipeline of Small Molecule Drugs for Oncology, Autoimmune Disorders

    BlossomHill Therapeutics raised $71 million in a Series A financing round, led by Cormorant Asset Management LLC and joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and…

    TrialSite Staff
    TrialSite Staff March 5, 2021
    0 Comments
    Caribou Bio Secures $115M to Advance CRISPR Platform and Allogeneic Cell Therapy Pipeline

    Caribou Bio Secures $115M to Advance CRISPR Platform and Allogeneic Cell Therapy Pipeline

    Caribou Biosciences announced the successful completion of an oversubscribed $115 million Series C financing, co-led by new premier healthcare investors Farallon Capital Management, PFM Health…

    TrialSite Staff
    TrialSite Staff March 4, 2021
    0 Comments
    Load More

    Read more about…

    Alzheimer Alzheimer's Disease Artificial Intelligence Autoimmune Disease Breast Cancer Cancer Cardiovascular Challenging Results China Clinical Research Clinical Research as a Care Option Clinical Trials CNS Coronavirus covid-19 COVID-19 Dementia Diabetes Digital Health Digital Media FDA Gene Therapy Immunotherapy India Investigator Content Investigator Profiles Investor Watch Ivermectin Leading Pharma Leading Sites Neurology NIH Oncology Patient Recruitment Pharma Watch Positive Results Price Watch Prostate Cancer Research SARS-CoV-2 Site Challenges Site Success Site Watch UK Vaccine

    About Us

    TRIALSITE NEWS IS  DEDICATED TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

    © 2021 - Trial Site News
    • Terms of Service
    • Privacy Policy

    TrialSite News
    159 W Broadway, Suite 200
    Salt Lake City, UT 84101

    Report Content

    Harassment or bullying behavior
    Contains mature or sensitive content
    Contains misleading or false information
    Contains abusive or derogatory content
    Anything overly promotional selling products or services

    Block Member?

    Please confirm you want to block this member.

    You will no longer be able to:

    • See blocked member's posts
    • Mention this member in posts
    • Invite this member to groups
    • Message this member
    • Add this member as a connection

    Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.